Australian nano-biotech Nexsen Limited to debut on ASX with world-first diagnostic platform spanning human health, agriculture and biosecurity

Sydney, Australia, October 13, 2025: Each year, 1.9 million newborns die from preventable infections - 40% during labour - that could have been detected and treated - if only clinicians had faster, more reliable diagnostic tools. One Australian company is preparing to change that global statistic.

Nexsen Limited (ASX: NXN), a Melbourne-based nano-biotechnology innovator, will debut on the Australian Securities Exchange this Tuesday 14th October 2025 at 12:30 pm AEDT, with a world-first biosensing platform that delivers laboratory-grade results in minutes, not days. Designed for use anywhere - from hospital wards to farms and border checkpoints - the platform enables rapid, low-cost, and highly accurate disease detection.

The company’s first target is Group B Streptococcus (GBS), a bacterial infection responsible for more than 150,000 stillbirths and newborn deaths globally each year. Nexsen’s GBS Rapid Sensor allows clinicians to test expectant mothers during labour, producing results within minutes and giving medical teams the ability to intervene in real time - a breakthrough that could transform maternal and neonatal care worldwide.

At the core of Nexsen’s technology is a proprietary biosensing system that combines ultra-bright nanoparticles, high-affinity bioreceptors and modular lateral flow design. This enables portable, lab-quality testing in a handheld format - opening the door to applications across human health, agriculture and biosecurity.

Beyond maternity wards, Nexsen is adapting the platform for other major challenges, including bovine mastitis, a $32 billion global burden on dairy producers, and plant pathogens such as Xylella and Huanglongbing, which threaten fruit and horticultural industries around the world.

“Our mission is to make lab-quality diagnostics accessible wherever they’re needed - in hospitals, on farms, or at border checkpoints,” said Mark Muzzin, Founder and Managing Director of Nexsen Limited. “By combining scientific precision with real-world practicality, we intend to help prevent losses measured not only in dollars, but in lives.”

Supported by more than $10.9 million in government and institutional funding, Nexsen’s development has been backed by the Australian Government’s CRC-P and ARC programs, and advanced through RMIT University’s Sir Ian Potter NanoBioSensing Facility, under the direction of Professor Vipul Bansal, Nexsen’s Chief Innovation Officer and Chair of its Scientific Advisory Board.

“What makes this platform truly unique is its adaptability,” said Professor Vipul Bansal, Chief Innovation Officer at Nexsen and Director of the Sir Ian Potter NanoBioSensing Facility at RMIT University. “The same nanoscale material and the underlying flow chemistry and technology that allow us to detect a life- threatening infection in a newborn can also be tuned to identify disease in livestock or crops. It’s a modular system - one scientific foundation that can power hundreds of different diagnostic applications.”

Clinical trials for the GBS Rapid Sensor will commence in Q4 2025 in partnership with Northern Health (Victoria), with global commercialisation initially targeted across the United States, Europe, and Asia - representing more than 40 million births annually.

Media Enquiries:
Jane Morgan
Jane Morgan Management
E: [email protected] | M: 0405 555 618